- Home
- ANAB vs WASH Comparison
ANAB vs WASH Comparison
Compare ANAB & WASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- WASH
- Stock Information
- Founded
- ANAB 2005
- WASH 1800
- Country
- ANAB United States
- WASH United States
- Employees
- ANAB N/A
- WASH N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- WASH Major Banks
- Sector
- ANAB Health Care
- WASH Finance
- Exchange
- ANAB Nasdaq
- WASH Nasdaq
- Market Cap
- ANAB 759.5M
- WASH 647.4M
- IPO Year
- ANAB 2017
- WASH N/A
- Fundamental
- Price
- ANAB $20.55
- WASH $27.21
- Analyst Decision
- ANAB Buy
- WASH Buy
- Analyst Count
- ANAB 10
- WASH 2
- Target Price
- ANAB $36.38
- WASH $35.00
- AVG Volume (30 Days)
- ANAB 1.0M
- WASH 248.9K
- Earning Date
- ANAB 05-08-2025
- WASH 04-21-2025
- Dividend Yield
- ANAB N/A
- WASH 8.23%
- EPS Growth
- ANAB N/A
- WASH N/A
- EPS
- ANAB N/A
- WASH N/A
- Revenue
- ANAB $91,280,000.00
- WASH $98,251,000.00
- Revenue This Year
- ANAB N/A
- WASH $60.13
- Revenue Next Year
- ANAB $37.76
- WASH $9.09
- P/E Ratio
- ANAB N/A
- WASH N/A
- Revenue Growth
- ANAB 432.03
- WASH N/A
- 52 Week Low
- ANAB $12.21
- WASH $24.25
- 52 Week High
- ANAB $41.31
- WASH $40.59
- Technical
- Relative Strength Index (RSI)
- ANAB 65.12
- WASH 38.84
- Support Level
- ANAB $15.40
- WASH $26.57
- Resistance Level
- ANAB $19.82
- WASH $27.59
- Average True Range (ATR)
- ANAB 1.49
- WASH 1.32
- MACD
- ANAB 0.16
- WASH -0.05
- Stochastic Oscillator
- ANAB 96.26
- WASH 36.99
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About WASH Washington Trust Bancorp Inc.
Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates. The bank generates a majority of its revenue from the Commercial Banking segment.